Latest Lupus erythematosus Stories
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug BenlystaÂ® (belimumab), approved today by the U.S. Food and Drug Administration. BenlystaÂ®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
Lupus Research Institute Welcomes First New Treatment Approved For Lupus in More Than 50 Years NEW YORK, March 9, 2011 /PRNewswire-USNewswire/ -- The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations welcome the U.S.
First new lupus drug approved in 56 years SILVER SPRING, Md., March 9, 2011 /PRNewswire-USNewswire/ -- The U.S.
Alliance For Lupus Research Commits $500,000 To Glean Genetic Basis For Lupus In African Americans And Other Ethnicities Powerful ImmunoChip Technology Expands Range of Testing NEW YORK, March 9, 2011 /PRNewswire-USNewswire/ -- The Alliance for Lupus Research (ALR) - the world's largest private funder of lupus research - today announced funding of an important new study to identify lupus susceptibility genes in multiple ethnicities including African Americans, who are three times more likely...
Researchers at Dana-Farber Cancer Institute in Cambridge, Mass., in collaboration with Jackson Laboratory scientists, have identified a regulatory defect that drives lupus.
HAYWARD, Calif., Dec. 14, 2010 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.
Event Raises Crucial Funds for Lupus Research for 5 Million People Worldwide Living with Lupus NEW YORK, Dec. 9, 2010 /PRNewswire-USNewswire/ -- The Alliance for Lupus Research (ALR) honored Rupert Murdoch, News Corporation Chairman and CEO, at its 2010 One Love One Cause Gala event.
HAYWARD, Calif., Dec. 7, 2010 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.
NEW YORK, Nov. 16, 2010 /PRNewswire-USNewswire/ -- The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations are pleased with the U.S.
HAYWARD, Calif., Nov. 16, 2010 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc.